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these pilot data are unfortunately inconclusive. As centers
have adopted the RCP technique as a standard of care, these
data support the need for a multicenter randomized clinical
trial to compare safety and neurodevelopmental outcomes
of RCP with those of DHCA before broad institutionaliza-
tion on RCP.
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Discussion
Dr Frank L. Hanley (San Francisco, Calif). Thank you. I have no
conflicts.
I congratulate Dr Goldberg and her colleagues for a very timely
study and for an excellent manuscript and presentation. Sorting out
the relative neurodevelopmental morbidity of DHCA and continuous
cardiopulmonary bypass in neonatal heart surgery is a major chal-
lenge. As the authors imply, this is almost impossible to achieve in a
single-institution study. An important contribution of this study, how-
ever, is that it may act as a catalyst for further thought and possibly for
multi-institutional analysis. I have two comments to make and then a
couple of brief questions, and I hope you can bear with me. Most of
them relate to technique because technique is so important in neuro-
developmental outcome in terms of what we do in the operating room
as we are learning more and more.
The first comment relates to some very detailed technique issues.
I hesitate to dwell on these in this forum, but I believe they are
important. There are many ways to do RCP, and the details of how it
is done can affect the likelihood of neural injury. The technique used
in this study, using a polytetrafluoroethylene graft, which is cannu-
lated for RCP, requires a number of minutes of little or no innominate
artery perfusion during which the actual graft is being attached onto
the innominate artery. In addition, the technique requires, at least as I
understand it, several periods of DHCA, one when the central cannula
is transferred into the graft, one when the cannula is brought back to
its central position after most of the operation is done, and then when
the cardioplegic solution is given, because it is given through that
same cannula. So this involves three separate periods of circulatory
arrest. Furthermore, as you mentioned, there is another obligatory
period of very low unphysiologic flow, 5 mL · kg1 · min1, for
some undisclosed period of time. As a result, all RCP patients re-
ceived a period of circulatory arrest that was significant, a mean of 9
minutes overall in three separate settings, in addition to some unphys-
iologic flow. How much of this morbidity is found in this RCP group
and how it is related to these factors is actually impossible to tell. So
that is a major question that will have to be answered over time.
As a point of contrast, another way to perform RCP is to
directly cannulate the innominate artery with the arterial cannula at
the beginning of the case and to use that throughout. There is no
switching or further manipulation of the cannula, no periods of
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deliberate unphysiologic low cerebral blood flow, and no periods
of circulatory arrest. Cardioplegic solution is delivered directly
into the ascending aorta by a separate cannula and angiocath.
The point I am trying to make is not that one is better than the
other. We do not know, and I am sure anyone can make an
argument that this technique has certain disadvantages as well.
However, designing an effective multicenter study and really try-
ing to understand this is going to be a major challenge.
The second comment relates to the maturity of the two tech-
niques. DHCA techniques have been widely used and fine tuned
over many decades. RCP has been used much less widely and for
much shorter periods of time. Time and experience have made and
inevitably will continue to make both techniques safer, but with
DHCA we will never get away from the fact that the brain is being
starved of nutrients the second the pump is turned off. RCP has not
had the benefit of nearly the amount of experience or fine tuning
that DHCA has had, and furthermore, its problems and current
limitations are easily understood and much more solvable than
figuring out how to make the brain happy when there is no blood
flow going to it. We are not even close to identifying the ideal way
to do RCP at this point in time.
This comment is meant to be general, but it also applies directly to
the study. My understanding of the standard technique at the Univer-
sity of Michigan is that DHCA has been used for quite a long time,
many decades. So it is a good bet that the authors have pitted their
RCP learning curve against their decades long, finely tuned circula-
tory arrest technique in this study. For all of these reasons, the
long-term bet may well be on RCP, but we certainly do not know.
I would invite your responses to those two general comments,
and then I have two specific questions.
Why did you use 18°C as your level of hypothermia when there
is continuous perfusion? At this level, both the warming and
cooling times are substantially increased and therefore overall
cardiopulmonary bypass may well be lengthened unnecessarily.
This is another variable that certainly has not been worked out but
may well need to be addressed. I am just wondering why you
picked that same level of hypothermia.
The second question is also technical and it relates to venous
cannulation. During your RCP did you use a single venous can-
nula, which can be cumbersome when you have continuous per-
fusion, or did you use bicaval cannulation with snares, and did you
use a left ventricular vent? I hate to put you in this position because
I know you are not a surgeon, but these issues are very important,
both in terms of how long you are going to be on bypass, how well
you can do the operation, and in terms of embolic phenomena. If
you do not have a vent in place with a single venous cannula, you
easily can capture air in the ventricle that cannot be removed, and
this may have implications as well.
Dr Goldberg. Thank you very much, Dr Hanley, for those very
pertinent points and excellent questions. As you commented, I am
not a surgeon but I will try to address your questions. I know Dr
Ohye and Dr Bove are in the room. Please feel free to interrupt me
at any time.
To start off with your comments, this is a very difficult group to
study. Patients with HLHS have multiple periods of time during their
lives where they may have hemodynamic instability or be at risk for
things that we think put them at risk for neurodevelopmental abnor-
malities. You stated that a multicenter study is necessary but would be
a challenge. I agree that it will be a challenge for all the reasons you
described, including that there are multiple technical issues that need
to be resolved regarding the delivery of RCP.
You asked about the timing of DHCA in those patients ran-
domized for RCP. For the patients who were able to continue with
the RCP technique, excluding the 3 patients who required conver-
sion to DHCA, the mean time of DHCA was about 7 minutes.
There were, as you outlined, three separate brief periods of DHCA,
the longest of which is approximately 3 minutes for the delivery of
cardioplegic solution. However, I do not suspect that many would
argue that a 3-minute period of DHCA would significantly affect
neurodevelopmental outcome. There was a single cannula tech-
nique used as well.
Now, why use a temperature of 18°C? The reason we decided
to continue to cool the patients at 18°C was that if RCP needed to
be abandoned, then DHCA could be instituted immediately with-
out any delay. In addition, we had no proof that RCP was actually
neuroprotective, and therefore we wanted to take all prudent mea-
sures to protect the central nervous system.
Dr Charles D. Fraser (Houston, Tex). Again, congratulations
on a beautifully presented study and for bringing to light the
importance of a multicenter trial to try and get at the truth about
what many of us feel biased about. I wanted to also embellish on
Dr Hanley’s thoughts about the actual technique of the RCP.
You stated in your presentation that the perfusion flow rate was 20
mL · kg1 · min1, and a really important question then is how was
that decided on and how are we confident that that is an adequate
cerebral perfusion rate? In other words, how did you determine
adequacy of cerebral perfusion during the bypass period?
Dr Goldberg. We decided on the technique early on when we
started this study in 2001.When we designed this study, we based
our flow rates on the prior studies and descriptions of RCP and
data from animal models available at that time. I realize that
different flow rates have been used in more recent literature.
However, some authors caution that an increased flow rate may
increase the risk of cerebral edema. In addition, we are not aware
that there have been any studies to suggest that one flow rate is
clearly superior to any other. There are all sorts of issues to consider,
but we were consistent at aiming at 20 mL · kg1 · min1. The
patients were monitored with cerebral oximetry, but in talking with
the surgeons, they never needed to modify the flow rate based on
the cerebral oximetry data with saturations on RCP maintained
between 70 and 90.
Dr Paul Kurlansky (Miami, Fla). This is not so much a clinical
question as an experimental one. As an increasing amount of infor-
mation is becoming available about the biochemistry of reperfusion
injury, I was wondering whether you are aware of any studies in the
laboratory, at least, if not clinically, to take the opportunity of the time
period of ischemic arrest in the reperfusion model to supply substrates
that might ameliorate the reperfusion injury that would occur neces-
sarily at the time of complete reperfusion.
Dr Goldberg. Are you asking whether there are any treatments
that can be used during RCP to ameliorate reperfusion injury?
Dr Kurlansky. Correct, similar to the sort of substrate en-
hancement approach to cardioplegia.
Dr Goldberg. I apologize. I do not know the answer to that
question, whether there have been any medications or treatments or
perfected cooling or a perfect temperature that would optimize RCP.
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